Status:
COMPLETED
Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this phase II trial, we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer
Detailed Description
Upon determination of eligibility, all patients will be receive: * Topotecan
Eligibility Criteria
Inclusion
- To be included in this study, you must meet the following criteria:
- Small Cell Lung cancer
- Progression after one previous regimen
- Measurable or evaluable disease
- Able to perform activities of daily living with assistance
- Adequate bone marrow, liver and kidney function
- No more than three previous courses of radiation therapy
- Accessible for treatment and follow up
- Must give written informed consent prior to study entry
Exclusion
- You cannot participate in this study if any of the following apply to you:
- Central nervous system involvement
- Serious or active infection
- Serious underlying medical condition
- Other active neoplasms
- Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00193388
Start Date
September 1 2002
End Date
February 1 2007
Last Update
July 28 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.